GBP2

Across TCGA pan-cancer cohorts, GBP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GBP2 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher GBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GBP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where GBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.614	0.837	.001	23	view →
LUAD	DFS	Tertile	III,IV	0.831	0.453	.012	10	view →
LSCC	OS	Quartile	II,III,IV	0.539	0.929	.009	7	view →
HNSC	DFS	Quartile	All	0.886	1.000	.015	4	view →
CCRCC	OS	Median	II,III,IV	0.879	0.757	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GBP2–GBM (DFS)

Open the GBM breakdown →